LEBANON, N.H.–(BUSINESS WIRE)–Adimab, LLC, the global leader in the discovery and optimization of fully human monoclonal and bispecific antibodies, today announced a multi-target partnership with Boehringer Ingelheim (BI). Under the terms of the agreement, Adimab will use its proprietary platform to discover and optimize antibodies against targets chosen by BI, …
Tag Archives: Partnership
January, 2018
October, 2017
-
30 October
Boehringer Ingelheim and Sarah Cannon Research Institute to Investigate Novel Immuno-Oncology Combination Therapy
INGELHEIM, Germany & NASHVILLE, Tenn.–(BUSINESS WIRE)–Boehringer Ingelheim and Sarah Cannon Research Institute today announced an expansion of their strategic partnership to bring innovative treatments to cancer patients by developing novel immuno-oncology therapies. The new effort combines Boehringer Ingelheim’s oncology research and Sarah Cannon’s expertise in clinical trial design and recruitment …
March, 2015
-
5 March
Eisai and Merck Partner to Explore Novel Combination Regimens for Cancer
Japanese pharmaceutical firm Eisai has entered into a clinical trial collaboration to evaluate the combination of Merck’s anti-PD-1 drug with Eisai oncology compounds. The companies have teamed up to evaluate the safety, tolerability and efficacy of Merck’s Keytruda (pembrolizumab) in combination with Eisai’s Lenvima (lenvatinib) and Halaven (eribulin mesylate) in …